Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Enterprise Value: 2012-2025

Historic Enterprise Value for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $67.0 million.

  • Enanta Pharmaceuticals' Enterprise Value rose 333.78% to $67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$547.1 million, marking a year-over-year increase of 38.95%. This contributed to the annual value of $67.0 million for FY2025, which is 333.78% up from last year.
  • According to the latest figures from Q3 2025, Enanta Pharmaceuticals' Enterprise Value is $67.0 million, which was up 257.70% from -$42.5 million recorded in Q2 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Enterprise Value peaked at $1.3 billion during Q4 2021, and registered a low of -$139.0 million during Q4 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Enterprise Value averaged around $33.1 million, with its median value being -$28.7 million (2024).
  • Within the past 5 years, the most significant YoY rise in Enanta Pharmaceuticals' Enterprise Value was 333.78% (2025), while the steepest drop was 209.48% (2025).
  • Enanta Pharmaceuticals' Enterprise Value (Quarterly) stood at $1.3 billion in 2021, then plummeted by 40.28% to $753.0 million in 2022, then slumped by 118.46% to -$139.0 million in 2023, then skyrocketed by 31.77% to -$94.8 million in 2024, then soared by 333.78% to $67.0 million in 2025.
  • Its last three reported values are $67.0 million in Q3 2025, -$42.5 million for Q2 2025, and -$75.6 million during Q1 2025.